公司概述
Replimune Group, Inc. operates as a clinical-stage biotechnology entity dedicated to the development and commercialization of oncolytic immunotherapies specifically designed to treat cancer. The company's proprietary product candidates function by activating the immune system to target malignant cells, representing a specialized approach within the broader oncology treatment landscape. Operating within the Healthcare sector and the Biotechnology industry, the firm leverages these advanced therapeutic strategies to address unmet medical needs in cancer care. As of the latest reporting period, the company maintains a market capitalization of $596.17M and employs a workforce of 479 individuals. The current market cap of $596.17M, combined with a lack of reported annual revenue figures, indicates that the firm is in an investment stage where valuation is driven primarily by asset potential and pipeline progress rather than established commercial cash flows or market share dominance.
财务健康
The financial statements for Replimune Group, Inc. reveal a net income of $-314,852,992 over the trailing twelve months, alongside an EBITDA of $-318,880,992, reflecting the significant burn rate typical of early-stage clinical development. The gap between reported revenue (which is not available) and the substantial net loss of $-314,852,992 highlights a cost structure dominated by research and development expenditures rather than operating leverage from sales. The company generated a free cash flow of $-172,752,880, indicating a continued reliance on external capital sources to fund operations and clinical trials. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard characteristic for clinical-stage biotechs that have not yet achieved commercial product sales to generate revenue. On the balance sheet, the company holds $269.14M in cash against $76.35M in total debt, providing a substantial liquidity buffer despite the ongoing operational deficits. The debt-to-equity ratio stands at 36.26, suggesting a relatively low level of leverage relative to equity, while the current ratio of 5.60 indicates robust short-term liquidity and the ability to cover current obligations multiple times over. Return on Equity is reported at -90.9% and Return on Assets at -43.2%, metrics that reflect the dilutive impact of losses on shareholder equity and the efficiency of utilizing assets in the absence of profit generation.
估值评估
Valuation metrics for Replimune Group, Inc. present a mixed picture typical of pre-commercial biotechnology firms, with a trailing P/E ratio listed as N/A due to negative earnings and a forward P/E of -3.60. The negative forward P/E implies that the market is pricing in continued losses or expects earnings to turn positive significantly in the future, creating a disconnect with traditional valuation models based on profitability. The price-to-book ratio is 2.73, indicating that the market values the company at a premium of 173% over its book value, likely reflecting the high intangible value of its clinical-stage pipeline and intellectual property. Alternative valuation metrics such as the price-to-sales ratio are listed as N/A due to the absence of revenue, while the EV/EBITDA stands at -1.26, further confirming the company's negative earnings multiple status. Regarding trading ranges, the 52-week high is $13.24 and the 52-week low is $2.68, meaning the stock has experienced significant volatility within this $10.56 span. The beta of 0.77 suggests that the stock's price volatility is lower than the broader market, moving roughly 23% less than the market index on average.
Growth & Income
The reported growth rates for both revenue and earnings are listed as N/A, consistent with the company's current stage of development where historical commercial data is insufficient to calculate year-over-year percentage changes. In the absence of positive earnings growth, the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividend distribution is standard for clinical-stage firms, as the company retains all available cash to reinvest into its oncolytic immunotherapy pipeline rather than distributing returns to shareholders. Consequently, the overall growth and income profile is characterized by a total reliance on capital appreciation potential rather than income generation or consistent revenue expansion.